Transplanting Mesenchymal Stem Cells for Treatment of Ischemic Stroke.
Fan WangHailiang TangJianhong ZhuJohn H ZhangPublished in: Cell transplantation (2018)
Stroke is a major disease that leads to high mortality and morbidity. Given the ageing population and the potential risk factors, the prevalence of stroke and socioeconomic burden associated with stroke are expected to increase. During the past decade, both prophylactic and therapeutic strategies for stroke have made significant progress. However, current therapies still cannot adequately improve the outcomes of stroke and may not apply to all patients. One of the significant advances in modern medicine is cell-derived neurovascular regeneration and neuronal repair. Progress in stem cell biology has greatly contributed to ameliorating stroke-related brain injuries in preclinical studies and demonstrated clinical potential in stroke treatment. Mesenchymal stem cells (MSCs) have the differentiating potential of chondrocytes, adipocytes, and osteoblasts, and they have the ability to transdifferentiate into endothelial cells, glial cells, and neurons. Due to their great plasticity, MSCs have drawn much attention from the scientific community. This review will focus on MSCs, stem cells widely utilized in current medical research, and evaluate their effect and potential of improving outcomes in ischemic stroke.
Keyphrases
- atrial fibrillation
- mesenchymal stem cells
- stem cells
- risk factors
- umbilical cord
- cerebral ischemia
- end stage renal disease
- spinal cord
- cell therapy
- cardiovascular disease
- type diabetes
- newly diagnosed
- metabolic syndrome
- chronic kidney disease
- multiple sclerosis
- magnetic resonance imaging
- magnetic resonance
- computed tomography
- skeletal muscle
- cell proliferation
- signaling pathway
- peritoneal dialysis
- climate change
- blood brain barrier
- cardiovascular events
- patient reported
- contrast enhanced
- weight loss
- cell death
- wound healing